US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Cellectar Biosciences Inc (CLRBW)
Cellectar Biosciences Inc (CLRBW) ニュース

CLRBW

Cellectar Biosciences (CLRBW)

Cellectar Biosciences Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CLRBW

1 2 3 4 5 6 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2019/01/07	22 : 30	GlobeNewswire Inc.	Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma	NASDAQ:CLRBW	Cellectar Biosciences Inc
2019/01/03	22 : 30	GlobeNewswire Inc.	Cellectar Biosciences to Present at the Biotech Showcase	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/12/11	22 : 30	GlobeNewswire Inc.	Cellectar Granted Japanese Patent for CLR 131	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/12/04	22 : 30	GlobeNewswire Inc.	Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/11/13	22 : 30	GlobeNewswire Inc.	Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/11/12	22 : 30	GlobeNewswire Inc.	Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/10/02	21 : 00	GlobeNewswire Inc.	Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myelo...	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/09/27	21 : 30	GlobeNewswire Inc.	Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/09/25	21 : 30	GlobeNewswire Inc.	Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/09/24	21 : 00	GlobeNewswire Inc.	Cellectar Biosciences Provides an Update on the FDA Import Alert	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/09/17	21 : 30	GlobeNewswire Inc.	FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/08/29	21 : 30	GlobeNewswire Inc.	Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/08/20	21 : 30	GlobeNewswire Inc.	Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/08/13	21 : 00	GlobeNewswire Inc.	Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s Sarcoma	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/08/10	21 : 00	GlobeNewswire Inc.	Cellectar Reports 2018 Second Quarter Financial Results and Provides Business Update	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/08/01	21 : 30	GlobeNewswire Inc.	Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug Conjugate	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/08/01	05 : 05	GlobeNewswire Inc.	Cellectar Biosciences Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Op...	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/07/27	21 : 30	GlobeNewswire Inc.	Cellectar Biosciences Announces Pricing of $14.4 Million Underwritten Public Offering	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/07/18	21 : 00	GlobeNewswire Inc.	Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/07/17	21 : 00	GlobeNewswire Inc.	Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical ...	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/07/14	05 : 05	GlobeNewswire Inc.	Cellectar Announces 1-for-10 Reverse Stock Split	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/07/09	21 : 00	GlobeNewswire Inc.	Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/06/28	21 : 00	GlobeNewswire Inc.	Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/06/07	21 : 30	GlobeNewswire Inc.	Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/06/06	21 : 00	GlobeNewswire Inc.	FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Rhabdomyosarcoma	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/05/11	21 : 00	GlobeNewswire Inc.	Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/05/10	03 : 28	GlobeNewswire Inc.	Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/05/02	21 : 00	GlobeNewswire Inc.	Cellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat Neuroblastoma	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/04/17	21 : 00	GlobeNewswire Inc.	Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Mu...	NASDAQ:CLRBW	Cellectar Biosciences Inc
2018/04/16	21 : 05	GlobeNewswire Inc.	Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating the Ability of its PDCs to Selectively Target a Broa...	NASDAQ:CLRBW	Cellectar Biosciences Inc

Showing the most relevant articles for your search:NASDAQ:CLRBW

1 2 3 4 5 6 次へ >>

Vontobel Financial Produ...

iShares S&P TSX Canadian...

Blackrock Liquidity Funds CA Mon

Chroma (Chromia)

JP Morgan Fleming Overse... (PK)

Good Drinks Australia

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約